D

DaVita Clinical Research | Las Vegas, NV

Research site

(Unclaimed)

Location

2124 Tech Center Court, Suite 108, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

BI 685509

Bardoxolone Methyl

Atrasentan

VX-147

SNF472

Metformin

KBP-5074

LNP023

Parent organization

This site is a part of DaVita Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling

Primary IgA Nephropathy

Drug: LNP023

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular d...

Active, not recruiting

Immunoglobulin A Nephropathy

Alport Syndrome

Drug: Atrasentan

Locations recently updated

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147